“…This is exemplified by the synthesis of many Food and Drug Administration (FDA) approved active pharmaceutical ingredients (APIs), , including Terbinafine (Sandoz, squalene epoxide inhibitor), Ponatinib (Ariad Pharmaceuticals, tyrosine-kinase inhibitor), Tazarotene (Allergan, receptor-selective retinoid), and Eniluracil (GlaxoSmithKline, dihydropyrimidine dehydrogenase inactivator) . As reported by Sonogashira et al, alkynylation in the presence of copper salts proceeds under much milder conditions. ,, Copper additives, however, promote Glaser–Hay competitive homocoupling of alkyne and interfere with some functional groups potentially present in the coupling partners like azide, amine, and alkyne. During the isolation process, removal of copper cocatalyst may complicate the workup and purification, especially in the synthesis of APIs. , When it comes to a bulk industrial process, recovery of the precious metal from spent catalysts is more challenging for the copper cocatalyzed than the copper-free process. , Although homogeneous copper-free alkynylation has witnessed tremendous improvements, it mostly benefited from development of novel ligands ,,, and technologies.…”